Leuzy, A.
Ashton, N. J.
Mattsson-Carlgren, N.
Dodich, A.
Boccardi, M.
Corre, J.
Drzezga, A.
Nordberg, A.
Ossenkoppele, R.
Zetterberg, H.
Blennow, K.
Frisoni, G. B.
Garibotto, V.
Hansson, O.
Funding for this research was provided by:
H2020 European Research Council
Swedish Research Council
Knut and Alice Wallenberg Foundation
Marianne and Marcus Wallenberg Foundation
Strategic Research Area MultiPark (Multidisciplinary research in Parkinson disease) at Lund University
Swedish Alzheimer Foundation
Swedish Brain Foundation
Parkinson Foundation of Sweden
Parkinson Research Foundation
Skåne University Hospital Foundation
Bundy Academy
Swedish federal government under the Agreement for Medical Education and Research
Article History
Received: 12 October 2020
Accepted: 11 February 2021
First Online: 5 March 2021
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. OH has receiving grants from Roche, nonfinancial support from GE Healthcare, and grants from Biogen outside the submitted work.AL, NJA, NMC, AD, MB, CJ, AD, AN, RO, GBF, and GB report no conflicts of interest.